NIH reportedly loses 2 top leaders in 2 days
Two key staff members at the National Institutes of Health (NIH) are reportedly leaving the agency amid ongoing efforts by the Trump administration and Department of Government Efficiency head Elon Musk to drastically cut down the size of the federal workforce.
NIH Principal Deputy Director Lawrence Tabak told staffers in an email Tuesday he was retiring effective immediately, according to CBS News. Along with being principal deputy director, Tabak also served as the agency's deputy ethics counselor, having been appointed to both roles in 2010.
Tabak served as acting head of the NIH from December 2021 to November 2023, after the institute's former director Francis Collins stepped down.
As CBS reported, Tabak had not been expected to retire until the fall but told a colleague he felt it was necessary to retire at this time.
Just a day after Tabak's abrupt retirement, it was reported that Michael Lauer, deputy director of the National Institutes of Health's extramural research, will leave the agency at the end of the week.
According to STAT, acting NIH Director Matthew Memoli informed staff in an email of Lauer's departure, thanking him for his 'exemplary service to NIH and the American people.'
The Hill has reached out to the Department of Health and Human Services and the White House for comment.
These departures are occurring as the NIH is undergoing significant upheaval. Last week, the agency issued an order slashing federal funding for research projects, alarming lawmakers, universities and institutions across the country. The order has been stayed, though biomedical researchers remain wary for the future.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
28 minutes ago
- New York Post
New blood test can detect cancer 3 years before you start showing symptoms
Want to B-positive about your health? Johns Hopkins researchers have developed a cutting-edge blood test that can detect signs of cancer three years before any symptoms surface. The breakthrough could help doctors diagnose cancer long before today's screening tools allow, giving patients a better shot at beating the disease. Advertisement 3 Blood-based screening could one day compliment existing screening methods. Vadim – 'Three years earlier provides time for intervention,' Dr. Yuxuan Wang, an assistant professor of oncology and lead researcher of the study, said in a statement. 'The tumors are likely to be much less advanced and more likely to be curable,' she added. For the study, Wang and her colleagues analyzed blood samples from 52 people involved in a large National Institutes of Health-funded research project on cardiovascular health. Advertisement Half were later diagnosed with cancer within six months of giving blood. The rest stayed cancer-free. The researchers ran the samples through a multicancer early detection (MCED) test, which uses ultra-sensitive sequencing to hunt for tiny shards of mutated DNA that tumors leak into the bloodstream. It detected signs of cancer in 8 of the 26 future patients. Advertisement 3 Cancerous tumors shed genetic material into the bloodstream. Sebastian Kaulitzki – But here's the kicker: Six of those patients had older blood samples on file — and in four of them, early signs of cancer were already lurking more than three years before their diagnosis. 'This study shows the promise of MCED tests in detecting cancers very early, and sets the benchmark sensitivities required for their success,' said senior author Dr. Bert Vogelstein, a professor of oncology and co-director of the Ludwig Center at Johns Hopkins. Advertisement Right now, no MCED tests are fully approved by the FDA for widespread use, though some are commercially available under looser rules as Laboratory Developed Tests. While MCED tests aren't intended to replace standard screenings, experts say they could play an important role in spotting cancers earlier — especially those, like colon cancer, that are often diagnosed at advanced stages. 3 Several companies are developing MCED blood tests. Alexander Raths – 'Detecting cancers years before their clinical diagnosis could help provide management with a more favourable outcome,' said Nickolas Papadopoulos, a professor of oncology and senior author of the study. 'Of course, we need to determine the appropriate clinical follow-up after a positive test for such cancers,' he added. Among the eight participants whose cancers the MCED test detected months before diagnosis, five died from the disease — underscoring how deadly cancer can be when caught too late. For example, the five-year survival rate for breast cancer is 99% when detected early, but drops to less than 32% once the disease has spread, according to the American Cancer Society. Advertisement Excluding non-melanoma skin cancers, the group estimates more than 2 million new cancer cases will be diagnosed in the US in 2025 — with over 618,000 people expected to die from the disease. That breaks down to roughly 1,700 deaths every single day.
Miami Herald
32 minutes ago
- Miami Herald
What New ‘Big Beautiful Bill' Proposals Mean for Medicaid, SALT
Senate Republicans have revealed new proposals to modify President Donald Trump's "Big, Beautiful Bill," which would result in further changes being made to Medicaid, and a lower deduction of state and local taxes (SALT). On Monday, the GOP unveiled its recommended adjustments to Trump's bill, which included having work requirements for Medicaid enrollees who are parents of teens, and changing a previously updated $40,000 cap for SALT back to its current $10,000 deduction. The proposed changes have reportedly angered a number of House Representatives, according to Reuters, and lawmakers' opposing views on the legislation could make passing Trump's bill more complicated as the self-set deadline in July draws closer. Potential changes to the Medicaid system under Trump's bill have been sparking significant concern in recent months, such as the rolling back of Affordable Care Act (ACA) expansions and implementing work requirements. The Congressional Budget Office (CBO) estimated that as many as 13.7 million Americans would be left without health coverage by 2034 because of various new policies being brought in to transform the federal program. Meanwhile, the SALT cap deduction allows taxpayers who itemize when filing federal taxes to deduct certain taxes paid to state and local governments, which the 2018 Tax Cuts and Jobs Act (TCJA) capped at $10,000 per year for those filing jointly and $5,000 for single filers. This includes property taxes plus state income or sales taxes, but not both, according to the Tax Foundation. The proposals enhance the changes being made to Medicaid eligibility, which are being implemented as a major part of the legislation's cost-saving strategy. Previously, the House had exempted parents of dependents from Medicaid work requirements, but Senate Republicans are pushing for parents of children older than 14 to still fulfill the new expectations, of working a minimum of 80 hours a month. Work requirements have been divisive in both the House and Senate. Critics warn they will substantially weaken the Medicaid system, the largest public health insurance program in the country, by forcing millions off the service, while supporters of the plan argue that work requirements foster employment, reduce fraudulent claims, and improve personal responsibility. Senate Republicans are also proposing to maintain the $10,000 deduction cap, but that the amount is subject to continuing negotiations. This suggestion has allegedly drawn significant hit-back from House Republicans whose constituents would have benefited from the higher deduction, Reuters reported. "We have been crystal clear that the SALT deal we negotiated in good faith with the Speaker and the White House must remain in the final bill," the co-chairs of the House SALT caucus, Republican Representatives Young Kim and Andrew Garbarino said in a joint statement Monday. Republican Representative Nicole Malliotakis of New York posted on X, formerly Twitter, that the $10,000 cap in the Senate bill was not only insulting, but a "slap in the face to the Republican districts that delivered our majority and trifecta" with the White House. U.S. Senator for Maryland Chris Van Hollen wrote in a post on X: "The House version of Trump's so-called "Big, Beautiful Bill" cut $800B from Medicaid—and the Senate version is even worse. There's nothing "beautiful" about kicking millions off their health care. And to pay for billionaire tax cuts? We must fight this with everything we've got." U.S. Senator for Massachusetts Elizabeth Warren, wrote in a post on X: "House Republicans voted to kick 16 MILLION people off their healthcare. Today, Senate Republicans proposed BIGGER CUTS to Medicaid, just to fund bigger tax cuts for giant corporations. Call your senator." Republicans plan to bring the bill to a committee vote in the coming weeks, with a current scheduled deadline of July 4. This article contains reporting from The Associated Press. Related Articles Trump's Medicaid Cuts May Lead to Over 16,500 Deaths, New Study PredictsPennsylvanians Could Lose Access To Weight Loss Drugs Amid Medicaid ChangesMedicaid Expands Access for Tribes Across 6 StatesTrump Administration Shares Medicaid Data With Deportation Officials: Report 2025 NEWSWEEK DIGITAL LLC.
Newsweek
an hour ago
- Newsweek
How Cognizant Is Powering Health Care's Data Revolution
Health care is undergoing a fundamental transformation from a labor-intensive industry to a data-intensive sector, as artificial intelligence revolutionizes how health care organizations handle everything from insurance claims to drug discovery, representing the biggest operational shift since the introduction of electronic medical records. Take one of health care's most onerous administrative tasks: provider credentialing, the laborious process of enrolling doctors in insurance networks with varying coding across multiple insurance plans and geographic regions, which can consume weeks or months of work from dozens of staff members. "Now, with AI, we can get the task done within hours, if not minutes," explains Surya Gummadi, president of Cognizant Americas. AI is creating these kinds of efficiencies in back-office functions, faster clinical trials for pharmaceutical companies bringing treatments to market and real-time insurance authorization that helps health care providers streamline patient care decisions. Photo-illustration by Newsweek/Canva Cognizant, whose platforms are used by two-thirds of the U.S. insured population, approaches health care AI through what Gummadi calls three distinct vectors. Companies first enhance productivity through AI tools and models. They then focus on helping clients "infuse AI across their technology stack"—preparing data layers and applications for AI integration. And the final step, he says, is "agentification," which can coordinate multiple AI processes to handle complex tasks. "We have agentified our intranet," Gummadi explains. For example, if a Cognizant employee has a major life event, such as a new baby, they do not need to update their information in multiple systems for health insurance and paid time off. "Just one single update," he says, "and the agents across the intranet will coordinate and make it seamless for the associate." Anchoring Cognizant's role in the administrative backbone that keeps the American health insurance sector functioning is its $2.7 billion acquisition of TriZetto in 2014, which created one of the largest health care technology infrastructures in the United States. TriZetto's platforms serve approximately 350 health insurers, covering about 180 million lives, processing everything from claims adjudication to benefits enrollment. "We are not approaching AI as a technology solution," Gummadi says. "We are approaching AI as an enterprise solution to help our clients in their business outcomes." This focus on outcomes rather than technology has allowed Cognizant to address what he describes as "value pools that we never had access to," including core business functions that were previously kept in-house. This shift toward data-driven operations represents more than a technological upgrade—it's health care evolving into an industry where intelligent information processing, rather than human labor alone, drives core functions and patient outcomes. "Twelve months ago, most of the enterprises were a bit skeptical, and they were approaching AI more from an experimentation angle," Gummadi notes. "Now, many companies in different sectors are moving from experimentation to scale." While regulatory concerns initially slowed AI adoption in health care's highly regulated environment, there are now ways for organizations to "leverage AI by staying within the regulatory guardrails." And as health care organizations race to implement AI solutions, they increasingly opt for outside services rather than build proprietary systems. "There is a common agreement across clients and the service providers that there is no point in reinventing the wheel. So, there is more appetite for partnerships," Gummadi says. "All of us are racing against time when it comes to AI."
